Latest Pharmaceuticals News

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Sprintex Limited has landed US$321,000 in new purchase orders from its exclusive Indian distributor Euroteck, following the launch of its advanced GR Series Jet Blowers and a key commissioning at Delhi’s Kondli wastewater plant. This momentum underscores Sprintex’s growing footprint in India’s expanding wastewater treatment market.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Sigma Healthcare’s transformative merger with Chemist Warehouse has propelled the company into Australia’s top 20 ASX firms, with FY25 results exceeding expectations and synergy targets nearly doubling.